



ERS/ESTS Course Lung transplantation: Sharing experience across Europe

25-27 November 2021 Budapest, Hungary

Thursday, 25 November 2021

| 08:30-08:45 | Registration and welcome from the organisers |
|-------------|---|
| 08:45-09:00 | Welcome and identification of participants' learning needs - G. Massard |
| | Session 1 – Introduction Chair: G. Massard |
| | |
| 09:00-09:20 | History of lung transplantation – I. Inci |
| 09:20-10:00 | The key elements of a lung transplant programme - J. Gottlieb |
| 10:00-10:25 | Coffee Break |
| | Session 2 – Identifying and managing lung transplant candidates |
| | Chair: G. Verleden |
| 10:25-10:50 | Referral guidelines and specific criteria for candidate selection in CF, ILD, COPD and PH – G. Verleden |
| 10:50-11:15 | Candidate selection and management: specific controversial and ethical issues $- R$. Vos |
| 11:15-11:40 | Paediatric candidates: special issues – TBD |
| 11:40-12:05 | Mechanical ventilation and extracorporeal support prior to lung transplantation – A. Neyrinck |
| 12:05-13:00 | Lunch |
| | Session 3 – Donor organ availability |
| | Chairs: G. Massard |
| 13:00-13:30 | Pushing the boundaries of usable donors: marginal donors – I. Inci |
| 13:30–14:00 | Non heart-beating donors – A. Neyrinck |
| 14:00-14:30 | Ex-vivo donor lung perfusion – D. van Raemdonck |
| 14:30-15:00 | Size reduction and living lobar transplantation – G. Massard |
| 15:00-15:20 | Coffee Break |

Interactive workshops 1: Case examples and discussion

| 15:20–16:00 | Basic programme EVLP and reconditioning – TBD | Advanced programme Bridge with EC devices – D. van Raemdonck |
|-------------|--|--|
| 16:00–16:40 | Bridge with EC devices – D. van Raemdonck | NHBD management – A. Neyrinck |
| 16:40–17:20 | NHBD management – A. Neyrinck | EVLP and reconditioning – TBD |
| 17:30 | Welcome cocktai | il |

Friday, 26 November 2021

| | Session 4 – Early clinical care of the lung tran Chair: TBD | nsplant recipient | | |
|---|--|---|--|--|
| 08:30-09:00 | PGD physiopathology and prevention – I. Inci | | | |
| 09:00-09:30 | Primary graft dysfunction clinical management – A. Neyrinck | | | |
| 09:30-10:00 | Acute cellular rejection and humoral rejection – | | | |
| 10:00–10:30 | Pathological diagnosis of early complications (PGD, acute cellular and humoral rejection) – F. Calabrese | | | |
| 10:30-11:00 | Airway complication after lung transplantation – G. Massard | | | |
| 11:00–11:30 | Coffee Break | | | |
| Interactive workshops 2: Case examples and discussion | | | | |
| 11:30–12:15 | Basic programme PGD – A. Olland | Advanced programme Challenging pathological series – F. Calabrese | | |
| 12:15-13:00 | Challenging pathological series – F. Calabrese | PGD – A. Olland | | |
| 13:00-14:00 | Lunch | | | |
| | Session 5– Immunosuppression Chair: TBD | | | |
| 14:00-14:30 | What's new in induction therapy – TBD | | | |
| 14:30-15:00 | Standard IS regimens: CNI is still the cornerstone – R. Vos | | | |
| 15:00-15:30 | Alternative immunosuppressive strategies – J. C | | | |
| 15:30–16:00 | Coffee Break | | | |

| | Session 6 – Infections and the lung transplant candidate and recipient |
|-------------|--|
| | Chairs: TBD |
| 16:00–16:30 | Prevention and treatment of viral infections: CMV and other community respiratory viruses – M. Perch |
| 16:30-17:00 | Aspergillus and other fungi – M. Perch |
| 17:00-17:30 | Bacterial infections – A. Holm |
| 17:30-18:00 | Complications in paediatric lung transplantation – TBD |

Saturday, 27 November 2021

| | Session 7 – Chronic lung allograft dysfu Chairs: R. Vos | inction | |
|-------------|--|---|--|
| 08:30-09:00 | CLAD definition and CLAD phenotypes, definition and pathogenesis – G. Verleden | | |
| 09:00-09:30 | Immunoregulatory treatment: Strategies in BOS and RAS – F. Meloni | | |
| 09:30-10:00 | Treatment of risk factors – J. Gottlieb | | |
| 10:00-10:20 | Retransplantation for CLAD: indications, Massard | outcomes and ethical issues – G. | |
| 10:20-10:50 | Coffee Break | | |
| | Session 8 – Long term complications af Chairs: A. Holm | ter lung transplantation | |
| 10:50-11:20 | Renal dysfunction and cardiovascular disorders – F. Meloni | | |
| 11:20–11:50 | Lymphoproliferative disease and other malignancies – M. Perch | | |
| | Interactive session Chairs: R. Vos, A. Olland | | |
| 11:50-12:30 | Participant case discussion | | |
| 12:30-13:30 | Lunch | | |
| | Interactive workshops 3: Case example | s and discussion | |
| | Basic programme | Advanced programme | |
| 13:30–14:00 | CLAD – G. Verleden | Management of kidney failure – F. Meloni | |
| 14:00–14:30 | RAS – R Vos | Lung carcinoma – A. Olland | |
| 14:30-15:00 | Management of kidney failure – F. Meloni | CLAD – G. Verleden | |

| 15:00–15:30 | Basic programme PTLD diagnosis and management – F. Calabrese /M. Perch | Advanced programme RAS – R Vos |
|-------------|---|--|
| 15:30–16:00 | Lung carcinoma – A. Olland | PTLD diagnosis and management – F. Calabrese /M. Perch |

16:00–16:30 Course evaluation and closing remarks